Point-of-Care HIV Testing and Early Dolutegravir Use for Infants
Principal Investigator Initiated

Principal Investigator: Gbolahan Ajibola, MB, BS, MPH

Study Objectives

Primary Objectives

Post abortion care in Botswana: Impact of HIV status on outcomes
Principal Investigator Initiated

Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH

Study Objectives:

Post-acute sequelae of SARS-CoV-2 infection (PASC) / ‘Long Covid’: observational cohort: “Motlhala” Study
Principal Investigator Initiated

Principal Investigator - Dr. Shahin Lockman MD, MPH | Dr. Gaerolwe Masheto MD, PGDip FamMed | Dr. Kaelo Seatla MD

Study Objectives: Describe the prevalence and clinical manifestations of PASC in persons with confirmed SARS-CoV-2 (and comparator groups without history of SARS-CoV-2):

Potlako+ : A multilevel intervention to improve timely cancer detection and treatment initiation in Botswana
Principal Investigator Initiated

Principal Investigators - Dr. Scott Dryden-Peterson, MD, MSc | Dr. Neo M. Tapela, MD, MPH

Prevalence and outcomes of the usage of lumbar puncture in patients who presented with central nervous system symptoms at Princess Marina Hospital during the period 01/01/2014 to 31/03/2021
Principal Investigator Initiated

Principal Investigators - Nabila Youssouf PhD, Mosepele Mosepele MD, MSc | Sara Schwanke Khilji MD, MPH, FACP

Study Objectives: 

To determine the prevalence of lumbar puncture usage and outcomes of those who receive a lumbar puncture as compared to those who do not in patients who present to the hospital with neurological symptoms.

PRomoting Equity for Pregnant Adolescents in REsearch (PREPARE) in Botswana
Principal Investigator Initiated

Principal Investigator: Chelsea Morroni, MPH, MPhil, PhD, MBChB, DTM&H, DFSRH

Study Objectives:

 

Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants with Both Chronic Hepatitis B and HIV; v1.0 May 27, 2022; IND #158394; Site 12701/Gaborone
Principal Investigator Initiated

Principal Investigator: Ayotunde E. Omoz-Oarhe (MD, MPH)

Study Objectives:

Single, High-dose AmBisome to Reduce Excess mortality from Cryptococcal Meningitis (SHARE-CM)
Principal Investigator Initiated

Study Objectives: This is a 5-year (2021-2026) non-research grant funded by CDC to facilitate implementation of the short course regimen for the treatment of HIV-associated cryptococcal meningitis.

SOLIDARITY Trial: An international (multisite)randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care
Principal Investigator Initiated

Principal Investigator - Professor Mosepele Mosepele MD, MSc

Study Objectives: The primary outcome is in-hospital mortality from any cause, and the primary analyses are of mortality in all randomised patients. The major secondary outcomes are initiation of ventilation, and duration of hospital stay.

The diagnosis and treatment of Chlamydia Trachomatis and Neisseria Gonorrhea in Woman to prevent adverse neonatal consequences (Maduo/STI Study)
Principal Investigator Initiated

Principal Investigator - Dr. Chelsea Morroni, MD, MPH, PhD

Name of the study: The diagnosis and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant women to prevent adverse neonatal consequences (Maduo Study). 

Study Status: Recruiting 

Study Objectives 

The diagnosis and treatment of Chlamydia trachomatis and Neisseria gonorrhoeae in pregnant women to prevent adverse neonatal consequences.
Principal Investigator Initiated

Study Objectives:

The FACET Study: Family Dynamics and Child Neurodevelopment in Botswana
Principal Investigator Initiated

Principal Investigator - Kathleen Powis, MD, MPH, MBA | Michelle Bulterys PhD

Study Objectives:

Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV- Exposed Uninfected in Botswana
Principal Investigator Initiated

Principal Investigator - Dr. Jennifer Jao, MD, MPH

Study Objectives 

Primary Objectives

  • To assess the early longitudinal metabolic effects including insulin sensitivity in HIV-exposed uninfected (HEU) children compared to HIV-unexposed uninfected (HUU) children.
  • To determine differences in the effects of neonatal zidovudine (AZT) vs. nevirapine (NVP) prophylaxis on early longitudinal changes in insulin sensitivity in the first 3 years of life.

Secondary Objectives

Understanding the Mechanisms of Adverse Birth Outcomes in Botswana
Principal Investigator Initiated

Principal Investigator - Dr. Rebecca Zash, MD

Study Objectives: General and Specific

Virologic and Molecular characterization of HIV-1Strains in non-citizens in Botswana
Principal Investigator Initiated

Principal Investigator: Patrick T Mokgethi Bsc

Study Objectives:

Virologic responses among people with HIV on dolutegravir-based first line therapy in Botswana
Principal Investigator Initiated

Principal Investigator: Ontlametse T Bareng Bsc

Study Objectives:

The aim of the study is to:

Assessing barriers and facilitators to improving prenatal supplementation and preconception fortification in Botswana – a qualitative study
Network Studies

Study Objectives: 

CoVPN 5001: A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection.
Network Studies

Principal Investigator - Dr. Joseph Makhema MB.ChB, FRCP

Study Objectives 

Primary Objectives

Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings (IMPAACT 2016)
Network Studies

Primary Objectives

HPTN 084: A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
Network Studies

Principal Investigator - Dr. Shahin Lockman MD, MPH

Study Objectives

Primary Objectives

  • Efficacy: To evaluate the relative efficacy of oral CAB/CAB LA (oral run-in and injections, Steps 1 and 2) vs. daily oral TDF/FTC for HIV prevention (Steps 1 and 2). 
  • Safety: To evaluate the relative safety of oral CAB/CAB LA (oral run-in and injections, Steps 1 and 2) vs. daily oral TDF/FTC for HIV prevention (Steps 1 and 2). 

Secondary Objectives